PT830130E - Enzima de conversao de tnf-alfa - Google Patents

Enzima de conversao de tnf-alfa

Info

Publication number: PT830130E
Authority: PT; Portugal
Prior art keywords: alpha; tnf; conversation; enzyme; protease
Prior art date: 1995-06-08

Application number

PT96923209T

Other languages

English (en)

Inventor

Roy A Black

Charles Rauch

Douglas P Cerretti

Carl J March

Original Assignee

Immunex Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-06-08

Filing date

1996-06-03

Publication date

2004-11-30

1996-05-23 Priority claimed from US08/655,345 external-priority patent/US5830742A/en

1996-06-03 Application filed by Immunex Corp filed Critical Immunex Corp

2004-11-30 Publication of PT830130E publication Critical patent/PT830130E/pt

Links

102000004190 Enzymes Human genes 0.000 title 1
108090000790 Enzymes Proteins 0.000 title 1
108091005804 Peptidases Proteins 0.000 abstract 3
239000004365 Protease Substances 0.000 abstract 3
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 3
GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 abstract 1
102000005741 Metalloproteases Human genes 0.000 abstract 1
108010006035 Metalloproteases Proteins 0.000 abstract 1
238000003556 assay Methods 0.000 abstract 1
239000002299 complementary DNA Substances 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
229940124597 therapeutic agent Drugs 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Wood Science & Technology (AREA)
Virology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Biotechnology (AREA)
Pulmonology (AREA)
Microbiology (AREA)
Communicable Diseases (AREA)
Vascular Medicine (AREA)
Oncology (AREA)
General Engineering & Computer Science (AREA)
Biophysics (AREA)

PT96923209T 1995-06-08 1996-06-03 Enzima de conversao de tnf-alfa PT830130E (pt)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US48245895A	1995-06-08	1995-06-08
US50461495A	1995-07-20	1995-07-20
US08/655,345 US5830742A (en)	1995-06-08	1996-05-23	TNF-α converting enzyme
PCT/US1996/008407 WO1996041624A1 (en)	1995-06-08	1996-06-03	TNF-α CONVERTING ENZYME

Publications (1)

Publication Number	Publication Date
PT830130E true PT830130E (pt)	2004-11-30

Family

ID=27413615

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT96923209T PT830130E (pt)	1995-06-08	1996-06-03	Enzima de conversao de tnf-alfa

Country Status (13)

Country	Link
EP (1)	EP0830130B9 (pt)
JP (1)	JP4326022B2 (pt)
AT (1)	ATE274346T1 (pt)
AU (1)	AU712759C (pt)
CA (1)	CA2222650C (pt)
DE (1)	DE69633231T2 (pt)
DK (1)	DK0830130T3 (pt)
ES (1)	ES2227598T3 (pt)
IL (1)	IL122305A0 (pt)
NO (1)	NO323623B1 (pt)
NZ (2)	NZ312285A (pt)
PT (1)	PT830130E (pt)
WO (1)	WO1996041624A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6180403B1 (en)	1999-10-28	2001-01-30	Isis Pharmaceuticals Inc.	Antisense inhibition of tumor necrosis factor alpha converting enzyme (TACE) expression
US6255064B1 (en)	1996-03-01	2001-07-03	The Procter & Gamble Company	Disintegrin metalloprotease and its use
JP2000507943A (ja) *	1996-03-26	2000-06-27	グラクソ、グループ、リミテッド	腫瘍壊死因子αコンバーターゼ
US5853977A (en)	1996-07-12	1998-12-29	Schering Corporation	Mammalian TNF-α convertases
EP0912746A2 (en) *	1996-07-12	1999-05-06	Schering Corporation	MAMMALIAN TNF-$g(a) CONVERTASES
EP0988385A2 (en)	1997-01-21	2000-03-29	Human Genome Sciences	Tace-like and matrilysin-like polypeptides
CA2281085A1 (en) *	1997-02-25	1998-08-27	The Procter & Gamble Company	Use of a novel disintegrin metalloprotease, mutants, fragments and the like
US6551857B2 (en)	1997-04-04	2003-04-22	Elm Technology Corporation	Three dimensional structure integrated circuits
US6548633B1 (en)	1998-12-22	2003-04-15	Genset, S.A.	Complementary DNA's encoding proteins with signal peptides
ES2293718T3 (es) *	1998-02-04	2008-03-16	Immunex Corporation	Enzima convertidora de tnf-alfa cristalina y usos de la misma.
US6842704B2 (en)	1998-02-04	2005-01-11	Immunex Corporation	Crystalline TNF-α-converting enzyme and uses thereof
US6632667B1 (en)	1999-10-28	2003-10-14	Isis Pharmaceuticals, Inc.	Modulation of L-selectin shedding via inhibition of tumor necrosis factor-α converting enzyme (TACE)
EP1449538A1 (en)	2003-02-21	2004-08-25	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Inhibition of TACE or amphiregulin for the modulation of EGF receptor signal transactivation
WO2005030798A2 (en) *	2003-09-24	2005-04-07	Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services	TNFαCONVERTING ENZYME INHIBITORY AGENTS AND STIMULATORY AGENTS-
EP2061802A1 (en) *	2006-08-28	2009-05-27	Ares Trading S.A.	Process for the purification of fc-fusion proteins
KR101770312B1 (ko)	2006-08-28	2017-08-22	아레스 트레이딩 에스.에이.	Ｆｃ함유 단백질을 정제하는 방법
EP2670775A1 (en)	2011-02-01	2013-12-11	Cancer Research Technology Limited	Anti-tace antibody molecules and their uses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1991002756A1 (en) *	1989-08-16	1991-03-07	Cetus Corporation	Prohormone cleavage site blocking antibody
WO1991002540A1 (en) *	1989-08-16	1991-03-07	Cetus Corporation	Compositions for the inhibition of protein hormone formation and uses thereof
WO1992000378A1 (de) *	1990-06-22	1992-01-09	GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF)	Dna-sequenz für eine serin-protease und damit zusammenhängende gegenstände
EP0592423B1 (en) *	1990-08-06	2000-11-15	Chiron Corporation	Methods for the identification of cytokine convertase inhibitors
EP0648225A1 (en) *	1992-06-25	1995-04-19	Chiron Corporation	Compositions for the inhibition of protein hormone formation and uses thereof
CA2185162A1 (en) *	1994-03-07	1995-09-14	Robert F. Halenback (Deceased)	Compositions for the inhibition of tnf formation and uses thereof
JP2000507943A (ja) *	1996-03-26	2000-06-27	グラクソ、グループ、リミテッド	腫瘍壊死因子αコンバーターゼ

1996
- 1996-06-03 AU AU63781/96A patent/AU712759C/en not_active Ceased
- 1996-06-03 DE DE69633231T patent/DE69633231T2/de not_active Expired - Fee Related
- 1996-06-03 NZ NZ312285A patent/NZ312285A/en not_active IP Right Cessation
- 1996-06-03 JP JP50310797A patent/JP4326022B2/ja not_active Expired - Fee Related
- 1996-06-03 WO PCT/US1996/008407 patent/WO1996041624A1/en not_active Ceased
- 1996-06-03 NZ NZ510390A patent/NZ510390A/xx not_active IP Right Cessation
- 1996-06-03 CA CA002222650A patent/CA2222650C/en not_active Expired - Fee Related
- 1996-06-03 PT PT96923209T patent/PT830130E/pt unknown
- 1996-06-03 DK DK96923209T patent/DK0830130T3/da active
- 1996-06-03 ES ES96923209T patent/ES2227598T3/es not_active Expired - Lifetime
- 1996-06-03 AT AT96923209T patent/ATE274346T1/de not_active IP Right Cessation
- 1996-06-03 EP EP96923209A patent/EP0830130B9/en not_active Expired - Lifetime
- 1996-06-03 IL IL12230596A patent/IL122305A0/xx not_active IP Right Cessation
1997
- 1997-11-26 NO NO19975438A patent/NO323623B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
ES2227598T3 (es)	2005-04-01
AU712759C (en)	2001-08-09
EP0830130B9 (en)	2004-12-29
DE69633231D1 (de)	2004-09-30
EP0830130A1 (en)	1998-03-25
CA2222650A1 (en)	1996-12-27
NO975438D0 (no)	1997-11-26
DK0830130T3 (da)	2004-12-20
IL122305A0 (en)	1998-04-05
EP0830130B1 (en)	2004-08-25
MX9709744A (es)	1998-07-31
JP4326022B2 (ja)	2009-09-02
NZ510390A (en)	2002-11-26
JP2002515020A (ja)	2002-05-21
AU6378196A (en)	1997-01-09
EP0830130A4 (en)	2000-03-29
CA2222650C (en)	2009-10-13
ATE274346T1 (de)	2004-09-15
AU712759B2 (en)	1999-11-18
DE69633231T2 (de)	2005-08-04
NZ312285A (en)	2001-04-27
NO323623B1 (no)	2007-06-18
NO975438L (no)	1998-02-06
WO1996041624A1 (en)	1996-12-27

Publication	Publication Date	Title
PT830130E (pt)	2004-11-30	Enzima de conversao de tnf-alfa
BG103977A (en)	2000-11-30	Low molecular rotamase enzymic activity inhibitors
IT1260468B (it)	1996-04-09	Metodo per mantenere l'attivita' di enzimi proteolitici modificati con polietilenglicole
BG101841A (bg)	1998-04-30	Инхибитори на клетъчна адхезия
PT883687E (pt)	2005-02-28	Receptores de quimiocinas c-c, ckr-5, cc, os seus derivados e as suas utilizacoes
DK0966465T3 (da)	2003-10-20	Inhibitorer af IMPDH-enzymer
UY27972A1 (es)	2004-04-30	Derivados de hidantoína
EA200100103A1 (ru)	2001-06-25	Ингибиторы адгезии клеток
DK1053239T3 (da)	2003-04-22	Gluccocorticoid-selektive, anti-inflammatoriske midler
ATE199090T1 (de)	2001-02-15	Gegenüber eigenen inhibitoren resistente t-pa mutanten
TR199700803T1 (xx)	1998-02-21	Trombin-inhibit�rleri olarak yeni dipeptidik amidinler.
DE69729877D1 (de)	2004-08-19	Mycophenol bisphosponatverbindungen
MA26492A1 (fr)	2004-12-20	Inhibiteurs de proteases nouveaux et compositions pharmaceutiques les contenant .
DK1053240T3 (da)	2003-08-11	Glucocorticoid-selektiv antiinflammatoriske midler
ATE277943T1 (de)	2004-10-15	Trypsininhibitoren
ES2171563T3 (es)	2002-09-16	Nueva familia de inhibidores de proteasas, y otras sustancias de actividad biologica.
BR9814188A (pt)	2000-10-03	"agonistas de 5-ht1f"
MA26540A1 (fr)	2004-12-20	Composes nouveaux inhibiteurs de proteases et compositions pharmaceutiques les contenant.
FI951078A0 (fi)	1995-03-08	Retrovirusinfektion inhibitio
BR9608978A (pt)	1999-06-29	Inibidor de protease de serina derivado de imidazo [1,5a] piridina composição farmacêutica e utilização do inibidor de protease
WO1999001567A3 (en)	1999-04-01	Methods and compositions for a deubiquitinating enzyme and variants thereof
ATE281522T1 (de)	2004-11-15	Sentrin-spezifische menschliche protease senp1
CA2177600A1 (fr)	1995-06-15	Sequences d'acides nucleiques regulatrices et utilisations
DE60220185D1 (de)	2007-06-28	Screening-verfahren für substanzen zur behandlung von diabetes
EP0867449A4 (en)	2000-08-09	CELL ADHASION PROTEIN, THE CONTAINING IMMUNSUPPRESSIVE AGENT, AND IMMUNE SUPPRESSIVA, THE CELLS CONTAINED THAT WERE INDUCED